Asana: Benefits, Evidence, Dosage & Safety

TL;DR

I have read the asana evidence end to end, and here is where I land. An ICMR open trial in 93 type 2 diabetes patients found 12 weeks of Vijaysar heartwood lowered fasting glucose 32 mg/dl and postprandial 45 mg/dl. Encouraging. But the trial had no placebo, and this is not a diabetes-medication substitute.

What it is

Asana is the heartwood of Pterocarpus marsupium Roxb. (family Leguminosae/Fabaceae), a large deciduous tree native to central and southern India, also known as Vijaysar, Beejaka, and Indian kino tree (Wiley review).

The Ayurvedic Pharmacopoeia of India (Part I, Volume I) defines the official drug "Asana" as the heartwood of this species, listing Sanskrit synonyms including Beejaka, Pitasara, and Asanaka (API, Part I, Vol. I: Asana monograph). One detail I enjoy: the wood's water extract gives a yellow solution with blue fluorescence (API, Part I, Vol. I: Asana monograph). Practitioners used to check that.

Traditional use

In Ayurveda, formulations containing the heartwood of P. marsupium have been described as part of lifestyle-and-herb therapy for diabetes-like conditions (Madhumeha), with the heartwood a major portion of those preparations (Wiley review). The API monograph lists classical therapeutic uses including thirst, skin disorders, and blood disorders (API, Part I, Vol. I: Asana monograph).

These are traditional claims, not clinical proof. I keep that line bright in my head for this herb, because the human evidence below is genuinely more promising than usual, which makes it tempting to overread. The trials are assessed separately, on their own terms.

What modern research says

Blood sugar in humans

The most cited human data come from an Indian Council of Medical Research (ICMR) phase II open trial of Vijaysar (P. marsupium) conducted at four centers across India. Among 93 newly diagnosed or untreated non-insulin-dependent diabetes patients who completed 12 weeks of treatment, mean fasting blood glucose fell by 32 mg/dl and postprandial glucose by 45 mg/dl (from initial means of 151 and 216 mg/dl respectively, P<0.001), while other laboratory parameters remained stable and no side effects were reported (primary trial record, PubMed PMID 9745215).

Solid numbers. Now the asterisk, and it is a big one: this was an open (non-blinded) trial without a placebo group. Encouraging, not conclusive. I would not call it anything stronger than that.

A peer-reviewed review of the plant's antidiabetic evidence notes that several clinical trials have tested P. marsupium heartwood at a flexible dose of 2 to 4 g/day for 12 or 36 weeks and reported hypoglycaemic effects, alongside a separate clinical report of usefulness in non-obese diabetes (European Journal of Medicinal Plants review). Honest about the vintage: the underlying trials are old and small, and details of randomization and blinding are limited.

Blood sugar in animals

In vivo studies in streptozotocin-induced diabetic rats found that P. marsupium extracts reduced blood glucose levels and oxidative stress markers (Wiley review). Earlier work in alloxan-induced diabetic rats reported that bark extract had a small but significant hypoglycaemic effect in normal rats and a significant, dose-dependent antihyperglycemic effect in diabetic animals, and isolated phenolics (marsupsin and pterostilbene) significantly lowered blood glucose in hyperglycemic rats (Pharmacognosy Reviews).

Animal results do not automatically translate to humans. Here, though, they at least point the same direction as the human data, which is more than most herbs can say.

Antioxidant and anti-inflammatory effects

Beyond glucose lowering, extracts of P. marsupium have shown antioxidant activity in diabetic animal models, including reduced oxidative stress markers (Wiley review). In vitro work has identified constituents such as epicatechin and liquiritigenin with inhibitory effects on enzymes involved in glucose metabolism, including α-amylase (same review).

Laboratory findings. Not evidence of clinical benefit. I report them because they suggest mechanism, not because they should change anyone's decisions.

Dosage

There is no universally established dose. What exists is trial practice, and I will report exactly that.

In the ICMR open trial, Vijaysar was used at a flexible dose of 2 to 4 g/day for 12 weeks (control attained on 2 g in about 73%, 3 g in 16%, 4 g in 10%), with no side effects reported in that period (primary trial record, PubMed PMID 9745215). A separate primary clinical study used P. marsupium wood powder at 2–4 g/day for 12 weeks (IJBCP clinical study). Preparation type (crude powder, aqueous or ethanolic extract) varied between studies, so these doses do not directly transfer to any retail product. Do not assume the capsule on the shelf is what the trial tested.

Safety & contraindications

The ICMR open trial reported no side effects over 12 weeks in 93 patients (primary trial record, PubMed PMID 9745215). Beyond that single trial, published human safety data are limited.

The risk I take most seriously here is the obvious one: because the herb may lower blood sugar, combining it with diabetes medications could increase the risk of hypoglycaemia. This follows from its pharmacology, and anyone on glucose-lowering drugs should only use it under medical supervision. There are no reliable data on safety in pregnancy or breastfeeding. Safety data is limited overall, so talk to a clinician before use, especially if you take prescription medicines. I would not soften any of that.

FAQs

What is Asana used for in Ayurveda?

Traditionally, Asana (Vijaysar) heartwood is used in Ayurvedic formulations for diabetes-like conditions (Madhumeha), and the Ayurvedic Pharmacopoeia of India monograph lists classical uses including thirst, skin disorders, and blood disorders. The API defines the official drug as the heartwood of Pterocarpus marsupium Roxb. (Wiley review). These are traditional claims; clinical support is assessed separately above, and it is genuinely more substantive than usual.

Does Asana lower blood sugar?

In an ICMR open trial of 93 newly diagnosed type 2 diabetes patients, 12 weeks of Vijaysar treatment lowered mean fasting glucose by 32 mg/dl and postprandial glucose by 45 mg/dl (P<0.001) (primary trial record, PubMed PMID 9745215). A review notes several small clinical trials at 2–4 g/day reporting hypoglycaemic effects (EJMP review). My read: the evidence is preliminary and not a substitute for prescribed diabetes treatment. Promising is not proven.

Are Asana and Vijaysar the same thing?

Yes. Vijaysar (also spelled Vijayasara) is the common Hindi name for the heartwood of Pterocarpus marsupium Roxb., a large deciduous tree of central and southern India. Asana is the Sanskrit/Ayurvedic name for the same drug, and Beejaka and Indian kino are other synonyms (Wiley review). One plant, several names, same heartwood.

What dose was used in studies?

Human trials summarized in a peer-reviewed review used 2 to 4 g of heartwood per day for 12 to 36 weeks. One study reported glycaemic control in 69% of patients at 12 weeks and another in 86% at 36 weeks (EJMP review). Preparation types differed between studies, so retail products may not match what was tested. I would not dose myself off these numbers.

Is Asana safe?

The ICMR open trial reported no side effects over 12 weeks (primary trial record, PubMed PMID 9745215), but published human safety data beyond that are limited. Because it may lower blood sugar, it could add to the effects of diabetes medications; pregnancy and breastfeeding safety data are lacking. Talk to a clinician before use. The cleanest answer is: not enough data to say more than that.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use, especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.